Welcome to CETI
At CETI, our mission is to make groundbreaking diagnostic and treatment methods accessible to everyone. With a deep commitment to advancing healthcare, we aim to continuously evolve our concepts and improve patient outcomes. To further this goal, we are proud to introduce two key entities:
CETI Development Ltd.
Dedicated to expanding the global reach of our diagnostic and therapeutic methods, CETI Development Ltd. is responsible for establishing CETI® centers worldwide. These centers, modeled after our flagship “Paris Pilot Center,” will offer cutting-edge diagnostic services and treatments, including the provision of CERITINE® and EllioVir®.
CETI IT Ltd.
Focused on advancing technological support for ED diagnosis and treatments, CETI IT Ltd. develops a comprehensive IT platform that integrates collected data from our centers. This platform not only enhances our diagnostic and treatment processes but also supports ongoing clinical research, authorized by the ethical exploitation of this valuable data.
We are dedicated to shaping the future of healthcare through innovation, collaboration, and a patient-centered approach.
CERITINE®
Discovered and published as early as 1982 (R. Virag – Lancet), the erectile effects of medications injected
into the penis remain today the most effective medical treatment for ED. The patient discreetly injects themselves before sexual activity after easy training with a specialist.
CERITINE®, an internationally patented formulation (SOLO envelope notarized), tested and improved over nearly forty years of practice, has arrived at the most effective and safest formula today.
The main advantages of the self-injection concept are:
• Local action only (no side effects on the body)
• Supra-physiological reactions: duration independent of ejaculation, elimination of the frequent and devastating fear of sexual failure
• Autonomy in managing the treatment once the patient has mastered the technique
• Reversibility of the erection by the patient using a specific antidote, etilefrine (in the rare case of prolonged erection)
• The potential competitor, alprostadil marketed under the name Edex (CSP) or Caverject (Pfizer), is significantly less effective, often painful (for 30% of users), and lacks the extended erection management system. Other products on the market, such as Androskat® or Invicorp®, are less effective. As for Trimix-labeled mixtures, they are merely a simplification of CERITINE®.
CONTACT US
For inquiries or to learn more about our services, please don’t hesitate to contact us at the provided phone number. We look forward to serving you.
